Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/20448
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorKostiuk, I.-
dc.contributor.authorPolova, Z.-
dc.contributor.authorKosyachenko, K.-
dc.contributor.authorSavchenko, D.-
dc.date.accessioned2026-11-02T09:32:51Z-
dc.date.available2026-11-02T09:32:51Z-
dc.date.issued2026-
dc.identifier.citationKostiuk, I., Polova, Z., Kosyachenko, K., Savchenko, D. (2026). Implementation of the managed entry agreement framework in Ukraine: a national analysis of the pathway from health technology assessment to concluded agreements. ScienceRise: Pharmaceutical Science, 5 (63), 31–38. https:// doi.org/10.15587/2519-4852.2026.378478uk_UA
dc.identifier.issnUDC 615.12:614.2:339.13-
dc.identifier.issnDOI: 10.15587/2519-4852.2026.378478-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/20448-
dc.description.abstractThe aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics.The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics.uk_UA
dc.language.isoenuk_UA
dc.publisherScienceRise: Pharmaceutical Science № 5(63)2026uk_UA
dc.subjectmanaged entry agreements, health technology assessment, innovative medicines, public procurement, pharmaceutical policy, access to medicines, reimbursement, negotiation process, pharmaceutical companies, Ukraineuk_UA
dc.titleImplementation Of The Managed Entry Agreement Framework In Ukraine: A National Analysis Of The Pathway From Health Technology Assessment To Concluded Agreementsuk_UA
dc.title.alternativeIMPLEMENTATION OF THE MANAGED ENTRY AGREEMENT FRAMEWORK IN UKRAINE: A NATIONAL ANALYSIS OF THE PATHWAY FROM HEALTH TECHNOLOGY ASSESSMENT TO CONCLUDED AGREEMENTSuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації кафедри організації та економіки фармації

Файли цього матеріалу:
Файл Опис РозмірФормат 
Implementation Of The Managed Entry Agreement Framework In Ukraine.pdf916,07 kBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.